Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The announcement that a second breast cancer gene had been found (and patents applied for) little more than a year after it was mapped coincided with a report from a second group who also claimed to have discovered the gene.
The gene therapy community has swung from an excited and overoptimistic mood to one of disillusionment with the apparent slowness of progress and with the absence of truly therapeutic applications. Although gene therapy is yet to come of age, there can be no doubt that, in time, it will bear fruit.
Glutamic acid decarboxylase is attracting much interest because of its putative involvement in two clinical disorders: stiff-man syndrome and insulin-dependent diabetes. Here we discuss the clinical significance of an autoimmune response against CAD and consider how such information may help identify the disease mechanisms of these disorders.
Simple cost-effective strategies for genetic testing of HNPCC are proposed (pages 169–174), but many questions must be answered before testing for inherited forms of common cancers becomes a widespread reality.
A new minimally invasive device for the treatment of cerebral aneurysms called the Guglielmi detachable coil (CDC) system is described. A brief history of aneurysm treatment and the advantages of the new system are reported.
The disappearance of genetically modified CTLs following infusion into AIDS patients led to a surprising observation: What are the implications for active immunotherapy (pages 216–223)?
A coagulation factor expressed in human breast cancer has implications for the interaction of neoplastic cells with vascular endothelium (pages 209–215).
